Vivia Biotech
Vivia Biotech specializes in ex vivo assays and translational models to evaluate the efficacy and safety of cancer therapies, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Their platform enables simultaneous measurement of therapeutic efficacy and hematotoxicity in a native human microenvironment, supporting drug development and personalized medicine.
Industries
Nr. of Employees
small (1-50)
Vivia Biotech
Patents
1,2,4-oxadiazole derivatives as drugs modulating the GLP-1 peptide receptor
US-9050347-B2
View Details
1,2,4-oxadiazole derivatives as drugs modulating the GLP-1 peptide receptor
US-9050347-B2
View DetailsServices
Evaluation of compound-induced cytotoxicity on hematopoietic precursors and lineages using assays that preserve the bone marrow microenvironment.
Assays to measure depletion of CD34+ hematopoietic progenitor subsets in normal bone marrow or disease samples to screen candidates and guide personalized therapy decisions.
Ex vivo assays that simultaneously quantify ADC anti-tumor activity and hematopoietic toxicity to inform therapeutic window and mechanism-of-action studies.
Ex vivo T‑cell assays including proliferation, polyclonal activation, naive/memory subset analysis and cytokine release to evaluate immunomodulatory effects.
Ex vivo evaluation of monoclonal antibody mechanisms (complement activation, ADCC, ADCP, direct apoptosis) and patient stratification using bone marrow samples.
Combined workflows that retain treated cells after functional assays for downstream molecular characterization (sequencing or transcriptomics) to link phenotype to genotype or expression signatures.
Evaluation of compound-induced cytotoxicity on hematopoietic precursors and lineages using assays that preserve the bone marrow microenvironment.
Assays to measure depletion of CD34+ hematopoietic progenitor subsets in normal bone marrow or disease samples to screen candidates and guide personalized therapy decisions.
Ex vivo assays that simultaneously quantify ADC anti-tumor activity and hematopoietic toxicity to inform therapeutic window and mechanism-of-action studies.
Ex vivo T‑cell assays including proliferation, polyclonal activation, naive/memory subset analysis and cytokine release to evaluate immunomodulatory effects.
Ex vivo evaluation of monoclonal antibody mechanisms (complement activation, ADCC, ADCP, direct apoptosis) and patient stratification using bone marrow samples.
Combined workflows that retain treated cells after functional assays for downstream molecular characterization (sequencing or transcriptomics) to link phenotype to genotype or expression signatures.
Expertise Areas
- Hematotoxicity profiling
- Antibody-drug conjugate safety assessment
- Ex vivo translational model development
- Integrated functional and molecular profiling
Key Technologies
- Multiparametric flow cytometry
- Fixed volumetric acquisition for cytometry
- Ex vivo co-culture of tumor and bone marrow
- Cytokine release assays
News & Updates
Vivia Biotech showcased a novel ex vivo assay using patient bone marrow samples to evaluate the efficacy of Daratumumab, a monoclonal antibody for treating Multiple Myeloma, during the EHA Congress.
Vivia Biotech showcased a novel ex vivo assay using patient bone marrow samples to evaluate the efficacy of Daratumumab, a monoclonal antibody for treating Multiple Myeloma, during the EHA Congress.